Biotech VC firm Aglaia launches USD65m Oncology Fund
Dutch venture capitalist Aglaia has launched the Aglaia Oncology Fund II, backed by high-net-worth families. Investors will contribute a total of USD65 million to the fund, which has a final target of USD80 to USD100 million. The group of investors has been expanded to include several institutional investors, including



